Physician profile
Aria Dayani
NPI 1366672818
$14,079.73
in general payments reported to CMS, 2019-2025
42 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $3,975 · 2021: $5,431 · 2022: $2,343 · 2023: $366 · 2024: $338 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $6,000.27 | 2020-2022 | |
| Novo Nordisk INC | $1,222.27 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,024.19 | 2019-2025 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $693.44 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $561.31 | 2019-2024 | Evenity, Prolia, Repatha |
| Allergan, INC. | $487.86 | 2019-2020 | |
| Glaxosmithkline, LLC. | $438.93 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $373.95 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $314.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $297.09 | 2019-2022 | |
| Amarin Pharma, INC. | $284.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.39 | 2019-2022 | |
| Eisai INC. | $260.78 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $245.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $204.01 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aria Dayani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.